<DOC>
	<DOCNO>NCT02669953</DOCNO>
	<brief_summary>Age-related macular degeneration ( AMD ) one common disorder cause visual disability elderly people . AMD lead dysfunction loss photoreceptors central retina . Neovascular AMD ( nAMD ) affect visual function early disease process . The purpose study evaluate effect switch ranibizumab therapy current routine therapy use aflibercept eye recurrent persistent nAMD . 20 patient recurrent persistent nAMD , previously treat intravitreal ranibizumab one year include trial . Patients examine monthly interval 12 month follow-up . Examinations carry include : Best-corrected visual acuity ( BCVA ) use ETDRS chart 4m distance , Reading Performance ( RP ) , Standard ophthalmic examination ( SOE incl . funduscopy applanation tonometry ) , Optical coherence tomography ( OCT ) , Autofluorescence fundus image ( AF ) &amp; red-free autofluorescence fundus image ( RF ) , Color fundus photography ( CFP ) , Fluorescein angiography indocyaningreen angiography ( FLA/ICG ) , Microperimetry ( MP ) , well Non-invasive OCT base optical angiography ( AngioVue ) .</brief_summary>
	<brief_title>Aflibercept Recurrent Persistent CNV</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adults ≥ 50 year Patients treat ranibizumab due wet agerelated macular degeneration one year BCVA &gt; = 20/400 study eye use ETDRS Willingness ability comply regular visit Signed informed consent Any surgical treatment eye within 3 month prior baseline study eye History uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma mediation ) Aphakia absence posterior capsule ( exclude YAGcapsulotomy ) study eye Retinal pigment epithelial tear involve macula study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>